Literature DB >> 2162251

Paradoxical increase in DNA cross-linking in a human ovarian carcinoma cell line resistant to cyanomorpholino doxorubicin.

D H Lau1, K L Ross, B I Sikic.   

Abstract

The cyanomorpholino analog of doxorubicin (MRA-CN) is a potent cytotoxic agent which is known to cross-link DNA. A human ovarian carcinoma cell line, ES-2, was grown in increasing concentrations of MRA-CN from 0.1 to 0.5 nM. The resultant resistant subline, ES-2R, was 4-fold resistant to MRA-CN. DNA damage and repair in response to MRA-CN were compared in the parental and resistant cell lines using alkaline elution. DNA cross-links were detectable after 3-h incubation of the cells at 37 degrees C in MRA-CN at concentrations greater than or equal to 1.0 nM. Paradoxically, 2-fold more cross-links were detected in the ES-2R cells as compared with the ES-2 cells. This paradoxical difference in cross-links between the 2 cell lines was observed to increase with time of exposure to 2.5 nM of MRA-CN. Non-protein-associated DNA strand breaks were also detected in the 2 cell lines after exposure to 2.5 nM of the drug. The ES-2 cells consistently showed twice as many breaks as the ES-2R cells, which could explain the paradoxical higher apparent DNA cross-linking observed with the ES-2R cells after exposure to MRA-CN. Studies of the time course of cross-link repair after exposure to MRA-CN revealed that 75% of the DNA cross-links disappeared in the ES-2R cells by the end of 8 h in drug-free medium. In contrast, cross-links in the ES-2 cells were undetectable after 4 h, which coincided with a progressive increase in DNA strand breaks. The topoisomerase II level in the ES-2 cells was 2- to 4-fold higher than that in the ES-2R cells. However, proteinase K treatment of the lysed cells did not increase the number of apparent strand breaks produced by MRA-CN, suggesting that topoisomerase II may not be involved. These findings indicate that, in addition to DNA cross-linking, MRA-CN causes DNA strand breakage. Resistance to MRA-CN in the ES-2R cells is associated with more apparent DNA cross-linking and less DNA strand breakage, which may be a consequence of differences in DNA repair and/or nonspecific DNA degradation between the resistant and the sensitive cell lines.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2162251

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Stem cell pathways contribute to clinical chemoresistance in ovarian cancer.

Authors:  Adam D Steg; Kerri S Bevis; Ashwini A Katre; Angela Ziebarth; Zachary C Dobbin; Ronald D Alvarez; Kui Zhang; Michael Conner; Charles N Landen
Journal:  Clin Cancer Res       Date:  2011-12-05       Impact factor: 12.531

2.  Lessons from border cell migration in the Drosophila ovary: A role for myosin VI in dissemination of human ovarian cancer.

Authors:  Hiroyuki Yoshida; Wenjun Cheng; Jamie Hung; Denise Montell; Erika Geisbrecht; Daniel Rosen; Jinsong Liu; Honami Naora
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-14       Impact factor: 11.205

3.  The role of methoxymorpholino anthracycline and cyanomorpholino anthracycline in a sensitive small-cell lung-cancer cell line and its multidrug-resistant but P-glycoprotein-negative and cisplatin-resistant counterparts.

Authors:  W T van der Graaf; N H Mulder; C Meijer; E G de Vries
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 4.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

Authors:  D J Booser; G N Hortobagyi
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

5.  The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylation.

Authors:  Sandra Sernbo; Elin Gustavsson; Donal J Brennan; William M Gallagher; Elton Rexhepaj; Frida Rydnert; Karin Jirström; Carl Ak Borrebaeck; Sara Ek
Journal:  BMC Cancer       Date:  2011-09-24       Impact factor: 4.430

6.  Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.

Authors:  Corine M Beaufort; Jean C A Helmijr; Anna M Piskorz; Marlous Hoogstraat; Kirsten Ruigrok-Ritstier; Nicolle Besselink; Muhammed Murtaza; Wilfred F J van IJcken; Anouk A J Heine; Marcel Smid; Marco J Koudijs; James D Brenton; Els M J J Berns; Jozien Helleman
Journal:  PLoS One       Date:  2014-09-17       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.